Christopher Peetz, an officer and director of Mirum Pharmaceuticals, Inc., filed a Form 144 notice on November 4, 2026, disclosing a proposed sale of 20,000 shares of common stock following a stock option exercise.

Key Highlights

  • Proposed sale: 20,000 shares of Mirum Pharmaceuticals common stock, with an aggregate market value of $1,800,000.00.
  • Acquisition method: The shares were acquired via stock option exercise from the issuer on November 4, 2026, with cash payment.
  • Shares outstanding: According to the filing, 65,282,044 shares of common stock were outstanding at the time of the notice.
  • Broker: The proposed sale is to be executed through Morgan Stanley Smith Barney LLC Executive Financial Services, 1 New York Plaza, 8th Floor, New York, NY 10004.
  • 10b5-1 plan: The filing indicates a Rule 10b5-1 trading plan was adopted on March 2, 2026.
  • Prior sales in past 3 months: Peetz sold 30,000 shares on September 1, 2026 for gross proceeds of $2,960,319.00, and 20,000 shares on August 10, 2026 for gross proceeds of $1,978,346.00.

Christopher Peetz Discloses Proposed Common Stock Sale at Mirum Pharmaceuticals

According to the Form 144 filing submitted November 4, 2026, Christopher James Peetz, identified as both an officer and a director of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM), intends to sell 20,000 shares of the company's common stock. The filing lists an approximate sale date of November 4, 2026, on the NASDAQ exchange, with the sale to be facilitated by Morgan Stanley Smith Barney LLC Executive Financial Services. The aggregate market value of the proposed sale is disclosed as $1,800,000.00.

The filing states that the 20,000 shares proposed for sale were acquired on November 4, 2026 through a stock option exercise from the issuer, with cash provided as payment. Peetz is listed as the seller, with an address at 989 East Hillsdale Boulevard, Suite 300, Foster City, California 94404, which is also the address of Mirum Pharmaceuticals.

As required by Form 144, the filing also discloses Peetz's sales of Mirum Pharmaceuticals common stock during the preceding three months. Those sales included 30,000 shares sold on September 1, 2026 for gross proceeds of $2,960,319.00, and 20,000 shares sold on August 10, 2026 for gross proceeds of $1,978,346.00. The filing notes that the Rule 10b5-1 trading plan under which the sales are made was adopted on March 2, 2026. By signing the form, Peetz represented, as of the plan adoption date, that he did not know any material adverse information regarding the current and prospective operations of Mirum Pharmaceuticals that had not been publicly disclosed.

What Was Disclosed

Peetz filed a Form 144 notice disclosing a proposed sale of 20,000 shares of Mirum Pharmaceuticals common stock acquired via stock option exercise, with an aggregate market value of $1,800,000.00, under a Rule 10b5-1 plan adopted March 2, 2026.